Matching Items (4)
Filtering by

Clear all filters

137488-Thumbnail Image.png
Description
The manner in which plants are able to acquire plant nitrate (NO3-) varies depending on a combination of distinct processes between "root high-and low-affinity NO-3 transporters and the proton gradient that is generated by the plasma membrane H+-ATPase" (Paez-Valencia et al, 2013). In this study we analyzed the response to

The manner in which plants are able to acquire plant nitrate (NO3-) varies depending on a combination of distinct processes between "root high-and low-affinity NO-3 transporters and the proton gradient that is generated by the plasma membrane H+-ATPase" (Paez-Valencia et al, 2013). In this study we analyzed the response to limiting nitrate (0.5 mM) of seventy-four breeding lettuce (Lactuca sativa) lines derived from the cross Parade vs. Pavane. Parade had an enhanced root acidification capacity when grown under Nitrate limitation in comparison to Pavane, which had a poor root acidification capacity. Two successive experiments were conducted under distinct environmental conditions to evaluate the performance of the different breeding lines based on their ability to grow under nitrogen limitation as an indirect measurement of their ability to take up nitrate. Specific parameters were established in order to properly classify strong and weak breading lines based on the following characterizations: 1) Average fresh shoots and roots weights; 2) Color of leaves (green vs. yellow); and 3) Root acidification capacity. In essence, the measurement of these parameters is would allow for the identification of breeding lines that demonstrated enhanced performance under Nitrate limitation in order to observe if their performance correlated with root acidification capacity. The breeding line's biomass, indicated by the average fresh shoots and roots weights, determined the plant's ability to uptake Nitrogen; whereas, large biomass values indicated Nitrogen uptake, low values indicated a low Nitrogen uptake (Javadiyan, 2008). To determine Nitrogen nutrition, the colors of the plants' leaves were observed throughout the duration of the study; a green color demonstrated appropriate Nitrogen nutrition, whereas as a yellow color identified Nitrogen deficiency (Yang, 2003). In addition to the nutrients that composed the media in the agar plates, a pH indicator (Bromocresol Purple Dye) was utilized to monitor root acidification; the purple indicator transformed into a yellow color upon the occurrence of acidification. In both experiments, a direct correlation between the root acidification capacity and the biomass of each breeding line could not be determined. Strong breeding lines were identified when they demonstrated large biomass measurements, which were obtained from the average fresh shoots and roots, and also a proper nitrogen nutrition status, which was shown through their green leaf phenotypic characteristics. These two characterizations were significantly prevalent in four breeding lines (B9, B17, C1, and C21), which on average outperformed the parental lines (Controls: P12 and P13).
ContributorsGodinez, Denise Ivette (Author) / Gaxiola, Roberto (Thesis director) / Mor, Tsafrir (Committee member) / Sanchez, Charles (Committee member) / Barrett, The Honors College (Contributor) / Department of Life Sciences (Contributor) / Department of Speech and Hearing Science (Contributor)
Created2013-05
168508-Thumbnail Image.png
Description
The growing field of immunotherapy has generated numerous promising diseasetreatment platforms in recent years. By utilizing the innate capabilities of the immune system, these treatments have provided a unique, simplistic approach to targeting and eliminating cancer. Among these, the bispecific T cell engager (BiTEÒ) model has demonstrated potential as a

The growing field of immunotherapy has generated numerous promising diseasetreatment platforms in recent years. By utilizing the innate capabilities of the immune system, these treatments have provided a unique, simplistic approach to targeting and eliminating cancer. Among these, the bispecific T cell engager (BiTEÒ) model has demonstrated potential as a treatment capable of bringing immune cells into contact with cancer cells of interest and initiating perforin/granzyme-mediated cell death of the tumor. While standard BiTE platforms rely on targeting a tumor-specific receptor via its complementary antibody, no such universal receptor has been reported for glioblastoma (GBM), the most common and aggressive primary brain tumor which boasts a median survival of only 15 months. In addition to its dismal prognosis, GBM deploys several immune-evasion tactics that further complicate treatment and make targeted therapy difficult. However, it has been reported that chlorotoxin, a 36-amino acid peptide found in the venom of Leiurus quinquestriatus, binds specifically to glioma cells while not binding healthy tissue in humans. This specificity positions chlorotoxin as a prime candidate to act as a GBM-targeting moiety as one half of an immunotherapeutic treatment platform resembling the BiTE design which I describe here. Named ACDClx∆15, this fusion protein tethers a truncated chlorotoxin molecule to the variable region of a monoclonal antibody targeted to CD3ε on both CD8+ and CD4+ T cells and is theorized to bring T cells into contact with GBM in order to stimulate an artificial immune response against the tumor. Here I describe the design and production of ACDClx∆15 and test its ability to bind and activate T lymphocytes against murine GBM in vitro. ACDClx∆15 was shown to bind both GBM and T cells without binding healthy cells in vitro but did not demonstrate the ability to activate T cells in the presence of GBM.
ContributorsSchaefer, Braeden Scott (Author) / Mor, Tsafrir (Thesis advisor) / Mason, Hugh (Committee member) / Blattman, Joseph (Committee member) / Arizona State University (Publisher)
Created2021
157613-Thumbnail Image.png
Description
Glioblastoma (GBM) is a highly invasive and deadly late stage tumor that develops from abnormal astrocytes in the brain. With few improvements in treatment over many decades, median patient survival is only 15 months and the 5-year survival rate hovers at 6%. Numerous challenges are encountered in the development of

Glioblastoma (GBM) is a highly invasive and deadly late stage tumor that develops from abnormal astrocytes in the brain. With few improvements in treatment over many decades, median patient survival is only 15 months and the 5-year survival rate hovers at 6%. Numerous challenges are encountered in the development of treatments for GBM. The blood-brain barrier (BBB) serves as a primary obstacle due to its innate ability to prevent unwanted molecules, such as most chemotherapeutics, from entering the brain tissue and reaching malignant cells. The GBM cells themselves serve as a second obstacle, having a high level of genetic and phenotypic heterogeneity. This characteristic improves the probability of a population of cells to have resistance to treatment, which ensures the survival of the tumor. Here, the development and testing of two different modes of therapy for treating GBM is described. These therapeutics were enhanced by pathogenic peptides known to improve entry into brain tissue or to bind GBM cells to overcome the BBB and/or tumor cell heterogeneity. The first therapeutic utilizes a small peptide, RVG-29, derived from the rabies virus glycoprotein to improve brain-specific delivery of nanoparticles encapsulated with a small molecule payload. RVG-29-targeted nanoparticles were observed to reach the brain of healthy mice in higher concentrations 2 hours following intravenous injection compared to control particles. However, targeted camptothecin-loaded nanoparticles were not capable of producing significant treatment benefits compared to non-targeted particles in an orthotopic mouse model of GBM. Peptide degradation following injection was shown to be a likely cause for reduced treatment benefit. The second therapeutic utilizes chlorotoxin, a non-toxic 36-amino acid peptide found in the venom of the deathstalker scorpion, expressed as a fusion to antibody fragments to enhance T cell recognition and killing of GBM. This candidate biologic, known as anti-CD3/chlorotoxin (ACDClx) is expressed as an insoluble protein in Nicotiana benthamiana and Escherichia coli and must be purified in denaturing and reducing conditions prior to being refolded. ACDClx was shown to selectively activate T cells only in the presence of GBM cells, providing evidence that further preclinical development of ACDClx as a GBM immunotherapy is warranted.
ContributorsCook, Rebecca Leanne (Author) / Blattman, Joseph N (Thesis advisor) / Sirianni, Rachael W. (Thesis advisor) / Mor, Tsafrir (Committee member) / Anderson, Karen (Committee member) / Arizona State University (Publisher)
Created2019
132487-Thumbnail Image.png
Description
Fusion protein immunotherapies such as the bispecific T cell engager (BiTE) have displayed promising potential as cancer treatments capable of engaging the immune system against tumor cells. It has been shown that chlorotoxin, a 36-amino peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus), binds specifically to glioblastoma

Fusion protein immunotherapies such as the bispecific T cell engager (BiTE) have displayed promising potential as cancer treatments capable of engaging the immune system against tumor cells. It has been shown that chlorotoxin, a 36-amino peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus), binds specifically to glioblastoma (GBM) cells without binding healthy tissue, making it an ideal GBM cell binding moiety for a BiTE-like molecule. However, chlorotoxin’s four disulfide bonds pose a folding challenge outside of its natural context and impede production of the recombinant protein in various expression systems, including those relying on bacteria and plants. To overcome this difficulty, we have engineered a truncated chlorotoxin variant (Cltx∆15) that contains just two of the original eight cystine residues, thereby capable of forming only a single disulfide bond while maintaining its ability to bind GBM cells. We further created a BiTE (ACDClx∆15) which tethers Cltx∆15 to a single chain ⍺-CD3 antibody in order to bring T cells into contact with GBM cells. The gene for ACDClx∆15 was cloned into a pET-11a vector for expression in Escherichia coli and isolated from inclusion bodies before purification via affinity chromatography. Immunoblot analyses confirmed that ACDClx∆15 can be expressed in E. coli and purified with high yield and purity; moreover, flow cytometry indicated that ACDClx∆15 is capable of binding GBM cells. These data warrant further investigation into the ability of ACDClx∆15 to activate T cells against GBM cells.
ContributorsSchaefer, Braeden Scott (Author) / Mor, Tsafrir (Thesis director) / Mason, Hugh (Committee member) / Cook, Rebecca (Committee member) / School of Life Sciences (Contributor, Contributor) / Barrett, The Honors College (Contributor)
Created2019-05